RxDoctor Payments Data

Ian Foxall, MD

Internal Medicine · Wilmington, NCNPI 1528008109

Payments from drug & device makers

$11,061in general payments, 2019–2025

Across 678 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Pfizer$648
  • Amgen$609
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$11,061100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,061 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$175,878
Medicare patients
406
Services billed
1,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$56,813
RybelsusSemaglutide26$56,279
FarxigaDapagliflozin Propanediol38$53,303
OzempicSemaglutide35$52,558
JanuviaSitagliptin Phosphate31$36,328
JardianceEmpagliflozin24$36,255
InvokanaCanagliflozin31$30,788
MounjaroTirzepatide19$29,270
XareltoRivaroxaban22$25,783
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$21,538
JanumetSitagliptin Phos/Metformin Hcl14$19,102
MyrbetriqMirabegron11$14,491
Breo ElliptaFluticasone/Vilanterol13$8,229
Atorvastatin Calcium552$5,451
Wixela InhubFluticasone Propion/Salmeterol18$5,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,835$108,83761 claims
PfizerEliquis$648$56,81343 claims
Johnson & JohnsonInvokana, Xarelto$66$56,57253 claims
MerckJanuvia, Janumet$254$55,43045 claims
AstraZenecaFarxiga$1,279$53,30338 claims
Boehringer IngelheimJardiance$166$36,25524 claims
GSKTrelegy Ellipta, Breo Ellipta$295$29,76729 claims
Lilly USA, LLCMounjaro$1,035$29,27019 claims
Astellas Pharma US IncMyrbetriq$21$14,49111 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$12$4,605359 claims
AbbVieSynthroid$1,377$4,47251 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →